title: [Liposomal doxorubicin in patients with breast cancer and concomitant cardiovascular diseases - interdisciplinary expert opinion].
abstract: The use of liposomal doxorubicin in place of conventional form can significantly reduce the risk of clinically important cardiovascular complications of chemotherapy. The use of liposomal doxorubicin-containing regimen seems to be the most justified in treatment of breast cancer patients with coexisting cardiovascular diseases. The document defines the possible clinical scenarios for the use of chemotherapy with liposomal doxorubicin and presents the optimal cardiac monitoring of this therapy.
authors.affiliation: s.szmit@gmail.com.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Szmit
authors.forename: Krzysztof J
authors.initials: KJ
authors.lastname: Filipiak
authors.forename: Maria
authors.initials: M
authors.lastname: Litwiniuk
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Opolski
authors.forename: Piotr
authors.initials: P
authors.lastname: Wysocki
authors.forename: Beata
authors.initials: B
authors.lastname: Zaborska
authors.forename: Maciej
authors.initials: M
authors.lastname: Krzakowski
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000150:complications*; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D017410:Practice Guidelines as Topic
chemical_list: D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin
keywords: breast cancer; cardiotoxicity; cardiovascular diseases; liposomal doxorubicin